Get the Stockscreener App
6.135
1.76%
-0.115
Inmune Bio Inc stock is traded at $6.135, with a volume of 71,721.
It is down -1.76% in the last 24 hours and up +12.45% over the past month.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
See More
Previous Close:
$6.25
Open:
$6.29
24h Volume:
71,721
Relative Volume:
0.29
Market Cap:
$135.25M
Revenue:
$155.00K
Net Income/Loss:
$-30.01M
P/E Ratio:
-4.0362
EPS:
-1.52
Net Cash Flow:
$-11.98M
1W Performance:
-2.54%
1M Performance:
+12.45%
6M Performance:
-46.93%
1Y Performance:
-14.96%
1-Day Range:
$6.0401
$6.35
1-Week Range:
$5.67
$6.46
52-Week Range:
$4.78
$14.74
Inmune Bio Inc Stock (INMB) Company Profile
Name
Inmune Bio Inc
Sector
Industry
Phone
(858) 964-3720
Address
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-24-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-21-21 | Initiated | B. Riley Securities | Buy |
| Jan-22-21 | Reiterated | Maxim Group | Buy |
| Sep-01-20 | Initiated | BTIG Research | Buy |
| Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
View All
Inmune Bio Inc Stock (INMB) Latest News
INmune Bio, Inc. (NASDAQ:INMB) Q3 2024 Earnings Call Transcript - MSN
INmune Bio (NASDAQ:INMB) Releases Quarterly Earnings Results, Misses Estimates By $0.11 EPS - MarketBeat
Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way? - Simply Wall St
INmune Bio Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.48 loss in 3Q 2023) - Yahoo Finance
INmune Bio Inc (INMB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ... - Yahoo Finance
Earnings call: INmune Bio Q3 2024 results show progress in clinical trials - Investing.com
Inmune Bio Reports Increased Losses Amid Financing Efforts - TipRanks
INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update - The Manila Times
INmune Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
INmune Bio Q3 2024 Earnings Preview - MSN
Short Interest in INmune Bio, Inc. (NASDAQ:INMB) Increases By 5.6% - MarketBeat
INmune Bio Inc (INMB) Q3 2024 Earnings Report Preview: What To Look For - Yahoo Finance
INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB - The Manila Times
Highbridge Capital Management's Strategic Acquisition of INmune Bio Inc Shares - Yahoo Finance
INmune Bio (INMB) Scheduled to Post Quarterly Earnings on Thursday - MarketBeat
INmune Bio Says XPro1595 Promotes Remyelination, Key for Central Nervous System Diseases - MarketWatch
INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination - The Manila Times
INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024 - The Manila Times
Insider Stock Buying Reaches US$951.2k On INmune Bio - Yahoo Finance
Alliance Global Partners Begins Coverage on INmune Bio (NASDAQ:INMB) - MarketBeat
Reviewing Windtree Therapeutics (NASDAQ:WINT) and INmune Bio (NASDAQ:INMB) - Defense World
(INMB) Technical Data - Stock Traders Daily
INmune Bio stock hits 52-week low at $4.8 amid market challenges - Investing.com UK
INmune Bio, Inc. (NASDAQ:INMB) Sees Large Decrease in Short Interest - MarketBeat
INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit - The Manila Times
INmune Bio Inc (INMB) Q2 2024 Earnings Call Highlights: Promising Advances Amid Rising Costs By GuruFocus - Investing.com Canada
INmune Bio Inc (INMB) Q2 2024 Earnings Call Highlights: Promising Advances Amid Rising Costs - Yahoo Finance
Where are the Opportunities in (INMB) - Stock Traders Daily
Insider Buying: CFO and 10% Owner David Moss Acquires Shares of INmune Bio Inc (INMB) - GuruFocus.com
INmune Bio, Inc. (NASDAQ:INMB) CFO David J. Moss Buys 10,000 Shares - Defense World
Inmune Bio CFO buys $52,868 in company stock - Investing.com India
Inmune Bio CFO buys $52,868 in company stock By Investing.com - Investing.com South Africa
Analytical Overview: INmune Bio Inc (INMB)’s Ratios Tell a Financial Story - The Dwinnex
INmune Bio Inc [INMB] Investment Guide: What You Need to Know - Knox Daily
INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease - The Manila Times
INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal (NASDAQ:INMB) - Seeking Alpha
CVI Holdings LLC Purchases New Position in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
CVI Holdings LLC Takes $5.26 Million Position in INmune Bio, Inc. (NASDAQ:INMB) - MarketBeat
Raymond James Initiates Coverage of INmune Bio (INMB) with Outperform Recommendation - MSN
Achieve, INmune, Lenz stocks win bullish view from RayJay - Seeking Alpha
INmune Bio (NASDAQ:INMB) Coverage Initiated by Analysts at Raymond James - Defense World
INmune Bio reports progress in prostate cancer trial By Investing.com - Investing.com Australia
INmune Bio reports progress in prostate cancer trial - Investing.com
INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort - The Manila Times
UCB rapidly bolsters blockbuster potential for Bimzelx with 3 new FDA approvals - FiercePharma
What is the investor’s view on Immunic Inc (IMUX)? - US Post News
You might want to take a look at Inuvo Inc (INUV) now - SETE News
Imunon Inc (IMNN) may enjoy gains as insiders got busy in the recent days - Knox Daily
Gaining Ground: Universe Pharmaceuticals INC (UPC) Closes Lower at 0.29, Down -13.83 - The Dwinnex
Innate Pharma Advances Novel Cancer Treatment - TipRanks
Century Therapeutics, Inc. (NASDAQ:IPSC) Stake Cut by Federated Hermes Inc. - MarketBeat
Inmune Bio Inc Stock (INMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Inmune Bio Inc Stock (INMB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tesi Raymond Joseph | President and CEO |
Sep 12 '24 |
Buy |
6.38 |
15,380 |
98,048 |
1,554,106 |
| Moss David J | Chief Financial Officer |
Sep 12 '24 |
Buy |
6.38 |
7,690 |
49,024 |
1,275,869 |
| Juda Scott | Director |
Jun 25 '24 |
Buy |
7.27 |
5,000 |
36,350 |
71,603 |
| Juda Scott | Director |
Nov 10 '23 |
Buy |
6.95 |
7,000 |
48,650 |
37,000 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):